Efficacy and Safety of Two-Drug Regimens with Dolutegravir plus Rilpivirine or Lamivudine in HIV-1 Virologically Suppressed People Living with HIV
Viruses · 2023
DOI: 10.3390/v15040936 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Viruses, 2023. Verfasst von Carlos Dueñas-Gutiérrez und 11 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Division, Hospital Universitario Clínico de Valladolid, 47003 Valladolid, Spain. Hauptthemen laut MEDLINE: HIV Infections, HIV-1, Anti-HIV Agents, HIV Seropositivity. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The high effectiveness and safety of the two-drug (2DRs) strategy using dolutegravir (DTG) plus lamivudine (3TC) have led to international guidelines recommending their use for treatment-naive HIV patients. In virologically suppressed patients, de-escalating from 3DRs to DTG plus either rilpivirine (RPV) or 3TC has shown high rates of virological suppression.
Objectives
This study aimed to compare the real-life data of two multicenter Spanish cohorts of PLWHIV treated with DTG plus 3TC (SPADE-3) or RPV (DORIPEX) as a switch strategy, not only in terms of virological suppression, safety, and durability but also in terms of immune restoration. The primary endpoint was the percentage of patients with virological suppression on DTG plus 3TC and DTG plus RPV at weeks 24 and 48. The secondary outcomes included the proportion of patients who experienced the protocol-defined loss of virological control by week 48; changes in immune status in terms of CD4+ and CD8+ T lymphocyte counts and the CD4+/CD8+ ratio; the rate, incidence, and reasons for discontinuation of treatment over the 48-week study period; and safety profiles at weeks 24 and 48.
Methods
We conducted a retrospective, observational, multicenter study of 638 and 943 virologically suppressed HIV-1-infected patients in two cohorts who switched to 2DRs with DTG plus RPV or DTG plus 3TC.
Results
The most frequent reasons for starting DTG-based 2DRs were treatment simplification/pill burden or drug decrease. The virological suppression rates were 96.9%, 97.4%, and 99.1% at weeks 24, 48, and 96, respectively. The proportion of patients with virological failure over the 48-week study period was 0.01%. Adverse drug reactions were uncommon. Patients treated with DTG+3TC increased CD4, CD8, and CD4/CD8 parameters at 24 and 48 weeks.
Conclusions
We conclude that DTG-based 2DRs (combined with 3TC or RPV) in clinical practice were effective and safe as a switching strategy, with a low VF and high viral suppression rates. Both regimens were well tolerated, and ADR rates were low, including neurotoxicity and induced treatment discontinuations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Infectious Diseases Division, Hospital Universitario Clínico de Valladolid, 47003 Valladolid, Spain.
- Infectious Diseases Division, Hospital Universitario de Burgos, 09006 Burgos, Spain.
- Infanta Leonor University Hospital Research and Innovation Foundation, 28031 Madrid, Spain.
- Infectious Diseases Department, Hospital Universitario de Donostia, 20014 San Sebastián, Spain.
- Infectious Diseases Division, Hospital Universitario de La Princesa, 28006 Madrid, Spain.
- Infectious Diseases Division, Hospital Universitario Puerta de Hierro, 28222 Madrid, Spain.
ORCID-Profile: Carlos Dueñas-Gutiérrez, Luis Buzón, Roberto Pedrero-Tomé, Ignacio De Los Santos, Sara De la Fuente, Guillermo Pousada, Jesús Troya
Zitieren
APA
Dueñas-Gutiérrez, C., Buzón, L., Pedrero-Tomé, R., Iribarren, J. A., De Los Santos, I., De la Fuente, S., Pousada, G., Moran, M. A., Moreno, E., Ferreira, E., Gómez, J., & Troya, J. (2023). Efficacy and Safety of Two-Drug Regimens with Dolutegravir plus Rilpivirine or Lamivudine in HIV-1 Virologically Suppressed People Living with HIV. Viruses. https://doi.org/10.3390/v15040936
Vancouver
Dueñas-Gutiérrez C, Buzón L, Pedrero-Tomé R, Iribarren JA, De Los Santos I, De la Fuente S, et al. Efficacy and Safety of Two-Drug Regimens with Dolutegravir plus Rilpivirine or Lamivudine in HIV-1 Virologically Suppressed People Living with HIV. Viruses. 2023. doi:10.3390/v15040936
BibTeX
@article{DueasGutirrez2023,
author = {Dueñas-Gutiérrez, Carlos and Buzón, Luis and Pedrero-Tomé, Roberto and Iribarren, José A and De Los Santos, Ignacio and De la Fuente, Sara and Pousada, Guillermo and Moran, Miguel Angel and Moreno, Estela and Ferreira, Eva and Gómez, Julia and Troya, Jesús},
title = {Efficacy and Safety of Two-Drug Regimens with Dolutegravir plus Rilpivirine or Lamivudine in HIV-1 Virologically Suppressed People Living with HIV},
journal = {Viruses},
year = {2023},
doi = {10.3390/v15040936}
}
EUVIMED